ICUI

Business Context and Reporting Period

Company: ICU Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: ICU Medical is a leader in developing, manufacturing, and selling proprietary disposable medical connection systems for intravenous (I.V.) therapy. The company focuses on safety devices designed to prevent needlestick injuries and exposure to infectious diseases (Hepatitis B/C, HIV). Key products include the CLAVE needleless connector, custom I.V. systems, and the Punctur-Guard blood collection needles (acquired via Bio-Plexus in late 2002). The company is executing a strategic transition from a component manufacturer to a producer of complete I.V. systems.

Key Financial Metrics (Year Ended Dec 31, 2003)

Material Changes vs. Prior Period

• Revenue Growth Drivers: Revenue increased 22% primarily due to growth in custom I.V. systems (+50%), Punctur-Guard products (+6.2M, driven by full-year inclusion post-acquisition), and CLAVE products (+8%).
• Customer Concentration: Sales to Abbott Laboratories increased to 67% of total revenue (up from 57% in 2002). Conversely, sales to B. Braun dropped significantly as the CLAVE supply agreement was terminated in late 2002; B. Braun revenue fell from $9.9M in 2002 to $1.4M in 2003.
• Gross Margin Compression: Gross margin declined from 57% to 53%. Management attributes this to temporary factors including unabsorbed overhead during production improvements in San Clemente and lower initial margins on the newly integrated Punctur-Guard product line.
• Acquisitions: The company acquired Bio-Plexus (Oct 2002) and two Italian I.V. system manufacturers (June 2003) to expand product lines and manufacturing capacity.
• Capital Allocation: The company repurchased 589,292 shares of treasury stock for $15.3 million and invested $10.7 million in property and equipment (expansion in Mexico, Italy, and San Clemente).

Guidance, Outlook, and Risks

• Outlook: Management expects revenue growth in 2004 to be lower in percentage terms than 2003, though significant in dollar amount. Growth is expected to be driven by custom I.V. systems and Punctur-Guard products. Gross margins are expected to improve modestly in 2004 but likely remain below 2002 levels.
• Strategic Initiatives: Continued expansion of the "SetSource" program with Abbott (extended through 2014) and increased focus on international markets. The company plans to launch new I.V. connectors in 2004 pending FDA clearance.
• Key Risks:
  • Customer Dependence: Abbott accounts for 67% of revenue; loss of this relationship or deterioration of Abbott's market position would have a material adverse effect.
  • Competition: Intense competition from large manufacturers (Baxter, BD, B. Braun) and potential price erosion as the market shifts to needleless technology.
  • Regulatory: Dependence on FDA 510(k) clearances for new products; delays could impact revenue.
  • Legal: Ongoing patent infringement litigation against B. Braun Medical, Inc.
• Unusual Items: The company discontinued new lending activities through its subsidiary ICU Finance in October 2003 but will honor existing commitments ($4.0M unfunded).

Investor Verification Checklist

• Abbott Relationship: Verify the stability of the Abbott contract and the impact of Abbott's spin-off of its Hospital Products Division (Hospira) on future order volumes.
• B. Braun Transition: Confirm the rate at which former B. Braun customers are migrating to Abbott or independent distributors following the termination of the CLAVE supply agreement.
• Margin Recovery: Monitor Q1 and Q2 2004 gross margins to validate management's assertion that Punctur-Guard margins and San Clemente overhead issues are resolving.
• Custom I.V. Growth: Assess whether the 50% growth in custom I.V. systems is sustainable as the market matures and competition increases.
• Capital Expenditures: Review the utilization of the new sterilization facility in Mexico and the Italian acquisition to ensure they meet projected efficiency targets.